Mycobacteria and their world  by Stanford, John & Stanford, Cynthia
I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 1 ( 2 0 1 2 ) 3 –1 2
.sc ienced i rec t .comAvai lab le a t wwwjournal homepage: www.elsevier .com/ locate / IJMYCOReview Article
Mycobacteria and their worldJohn Stanford *, Cynthia Stanford
Department of Medical Microbiology, Royal Free and University College Medical School, London, UK
BioEos Ltd., Mill House, Claygate, Marden, Near Tonbridge, Kent TN12 9PE, UKContents2
dIntroduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Mycobacteria and the natural environment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4212-5
oi:10
* Cor
E-mInvestigational aspects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Skin-testing with tuberculins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
The antigens of mycobacteria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Leprosy and tuberculosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
Buruli ulcer—M. ulcerans disease. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
Other mycobacterial diseases occurring in man . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6The Immuno-pathological spectrum of mycobacterial infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6The Bacillus of Calmette and Guerin (BCG) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
Mycobacterium vaccae—an immunomodulator for prophylaxis and therapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Mycobacterium vaccae in prophylaxis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Mycobacterium vaccae in therapy for leprosy and tuberculosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Unexpected findings with M. vaccae . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Mycobacteria and cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8Immune modulation and genera related to mycobacteria. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8Tsukamurella inchonensis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Gordonia bronchialis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9Conclusions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Introduction external environment and the other in animal tissues, whereMycobacteria are ubiquitous, occurring everywhere in the
world, except perhaps the Polar Regions. In deserts they can
be found under rocks and among the dried roots of vegeta-
tion. Their favoured environmental habitat is close to, and
at the edges of, fresh water both flowing and static. Besides
their natural habitat in the environment, a few of their hun-
dred or so species have become strict or obligate pathogens,
and a number of species are opportunist pathogens, normally
living in the environment but with the capacity to invade ani-
mal tissues. Thus, mycobacteria have two worlds: one in the531/$ - see front matter  2012 Asian-African Society for Myco
.1016/j.ijmyco.2012.01.001
responding author at: BioEos Ltd., Mill House, Claygate, Marden,
ail address: jandcstanford@btinternet.com (J. Stanford).they live in complicated relationships with the immune sys-
tem. It is their pathogenic species causing leprosy, tuberculo-
sis and Buruli ulcer that have made the mycobacteria
notorious. The environmental species, seldom causing dis-
ease, have the greatest effects on the majority of healthy peo-
ple. They were probably at least part of the driving force
leading to the development of cell-mediated immunity during
evolution in all animals. Environmental contact regulates sus-
ceptibility to many conditions other than those of mycobacte-
rial aetiology and offers an unexpected means of protection
from, and treatment for, humanity’s most important diseases.bacteriology. Published by Elsevier Ltd. All rights reserved.
Near Tonbridge, Kent TN12 9PE, UK. Tel.: +44 (0)1892 730298.
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other aerobic genera of the Actinomycetales, the order of bac-
teria to which the mycobacteria belong.
Mycobacteria and the natural environment
Although mycobacteria, except for the strict pathogens, all
live in the environment of soil and water, their distribution
is dictated by physical and chemical conditions. There is evi-
dence that temperature, moisture, ultra-violet light, pH and
geography affect this. In deserts the predominant species
are chiefly of pigmented organisms, scotochromogens or pho-
tochromogens, of the slow-growing sub-genus. Their yellow
carotinoid pigments protect them from sunlight, the ultra-
violet bands of sunlight being lethal to non-pigmented
species.
Mycobacteria as a genus, by virtue of their thick cell walls,
generally survive drying and the effects of strong acids and
alkalis, enabling them to pass through animal gut and be de-
tected in faeces and in city sewerage outlets. The great major-
ity of tubercle bacilli which become extracellular in the
natural degradation of pulmonary lesions are either aeroso-
lised or swallowed, thus becoming widely distributed in soil
where they survive for long periods if protected from ultra-
violet light [1,2].
In fresh-water situations, fast-growing species exceed the
slow-growers and there is further selection by pH, some spe-
cies preferring acidic conditions and others alkaline condi-
tions. For example, Mycobacterium vaccae amongst fast-
growers and M. ulcerans amongst slow-growers are more com-
mon in neutral to acid conditions than they are in alkaline
ones.
Investigational aspects
In the early 1970s in an attempt to isolate M. ulcerans
from the Ugandan environment, an extensive geographical
survey of cultivable environmental species was carried
out [3].
There are three ways of assessing mycobacterial distribu-
tion in the environment:
(1) Bacteriological culture of environmental samples.
(2) Polymerase chain reaction (PCR) probing of environ-
mental samples.
(3) Differential skin-testing of the resident human popula-
tion.
All of these have been valuable. Culture sounds simple, but
the methods required to isolate organisms, generally more
slow-growing than much of the other environmental bacterial
flora, are time-consuming and not always effective. Nonethe-
less, culture of an organism, the identity of which can be con-
firmed by phenetic, antigenic or genetic analysis, is the only
absolute proof of its presence in an environment. PCR is gen-
erally reserved for searches for particular species, such as
M. ulcerans [4], and for non-cultivable species, such as the lep-
rosy bacillus [5]. Easier and faster is multiple skin-testing,
depending upon the detection of remembered cellularimmune responses in those living in the environment under
investigation [6,7].
Skin-testing with tuberculins
Skin-testing with tuberculins is carried out by intradermal
injection of soluble reagents prepared from various mycobac-
terial species. Reactions are read as diameters of induration
after 48–72 h. When dealing with reagents made from patho-
gens, qualitative differences in positive responses can also be
distinguished [8]. Safe and minimally invasive, these reagents
are no longer available under current drug-regulatory condi-
tions. However, in former times, enormous amounts of infor-
mation were obtained [6–12].
There are interpretational difficulties owing to interfer-
ence by previous vaccination with BCG, and to individuals
responding to different groups of mycobacterial antigens,
allowing a categorisation of responders [13,14]. Nonetheless,
through these tests the interaction between man and his
mycobacterial environment became apparent.
The antigens of mycobacteria
Immunodiffusion analysis of sonicate preparations of myco-
bacterial species against high titre antibodies raised in rabbits
gives rise to the following definitions of four antigenic groups
[15,16] (see Fig. 1):
(1) Group i antigens are shared between all mycobacterial
species and some of them are shared by all bacteria,
including mitochondria in animal cells [17].
(2) Group ii antigens are limited to the slowly growing
species.
(3) Group iii antigens are shared by many fast-growing
species.
(4) Group iv antigens are species-specific and limited to
single species, or to small groups of closely related
species [18].
In relation to these groups of bacterial antigens are the dif-
ferent categories of skin-test responders [13,14]:
(1) Category 1 responders react to group i antigens, respond-
ing positively to tuberculins prepared from any myco-
bacterial species.
(2) Category 2 responders do not produce positive
responses to any of the tuberculins at their standard
test concentrations; 10–20% of individuals fall into each
of categories 1 and 2.
(3) Category 3 responders react positively to the species-
specific antigens of the species encountered. This cate-
gory consisting of around 70% of individuals can be
used to determine which species are present in an
environment.
(4) Category 4 is a minor category of those reacting to the
group ii antigens of slow-growers [14].
Analysis of the results from category 3 responders reveals
the immunological significance of environmental contact,
Fig. 1 – The antigens of mycobacteria. The groups of antigens shown are those demonstrable in immunodiffusion studies of
sonicate preparations of mycobacterial species against high titre antibodies raised to them in rabbits. Similar groups of
antigens, and possibly others, can be demonstrated in tests of cellular immunity based on lymphocyte transformation and
multiple skin-testing. Group i antigens (common mycobacterial) are shared by all mycobacterial species, and other aerobic
Actinomycetales. Some of them are also shared with other bacterial families and with the ancient bacteria, known as
mitochondria, present in almost all animal tissue cells. These include the heat-shock-proteins of modern bacteria and the
stress proteins of mitochondrial origin expressed in stressed animal cells. Group ii antigens (slow-grower associated) are
shared by tubercle bacilli, Mycobacterium ulcerans and all the slowly-growing species of mycobacteria. Group iii antigens (fast-
grower associated) are shared by most fast-growing mycobacterial species. These antigens are not detectable in leprosy
bacilli, M. vaccae and some closely related species. Group iv antigens (species-specific) are limited to individual species, but
may show differences in distribution between sub-species and some sharing between closely related species, e.g. M. avium,
M. intracellulare, M. paratuberculosis and M. leprae-murium. In cell-mediated immunity, group i antigens are recognised
through Th1 mechanisms, whereas groups ii and iv antigens are best recognised by Th2 mechanisms.
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By skin testing with combinations of tuberculins prepared
from four different mycobacterial species (the quadruple
skin-testing system), the complications in interpretation can
be in part elucidated [6–12].
Leprosy and tuberculosis
These two mycobacterioses share many characteristics, yet
are also quite distinct. As pathogens, their world is the inter-
nal environment of animal tissues, with the complication of
the immune response. They share an immunological spec-
trum [19], of which each disease covers a part. Both leprosy
and tubercle bacilli (M. leprae and M. tuberculosis, respectively)
are intracellular pathogens, becoming extra-cellular when
bacilliferous lesions break down; both exhibit persistence,
the continued presence of living bacilli quiescent in the tis-
sues in the absence of clinical disease [20,21]. These persisters
may precede or follow active disease and can activate when-
ever the immunological situation is suitable for them. It is
estimated that three quarters of the world’s human popula-
tion carry tubercle bacilli without ever having had the clinical
disease. Skin testing with leprosin (soluble reagent from lep-
rosy bacilli harvested from experimentally infected armadil-
los) suggests that many people in leprosy-endemic
countries are infected with leprosy bacilli. When immunityis perturbed, as with human immunodeficiency virus (HIV)
infection, endogenous activation of tuberculosis persisters
occurs and susceptibility to exogenous infection is increased.
In both leprosy and tuberculosis the question remains open
as to whether persisters are complete, cell-walled organisms,
or cell-wall free [22–24].
Whereas infectious particles of tuberculosis are dried
droplet nuclei of aerosols exhaled from the lungs, those of
leprosy are from the nose. They are considered the major
source of new infections, with fomites and environmental
aerosols occasionally giving rise to disease. These latter are
thought to be the source of many opportunist pulmonary
infections with water-borne, slow-growing species [25,26].
The site of primary infection in tuberculosis is generally
the periphery of the lung, whereas that of leprosy is thought
to be the nasal mucosa [27]. Both diseases are associated with
derangement of cellular immunity, and antibodies probably
have little part to play beyond the establishment of infection.
Infective particles of tubercle bacilli are thought to be small
clumps of fewer than five bacilli, larger clumps being caught
in the mucus flow of the airways and transported to the
gut, a site much less susceptible to infection [28]. The same
principles are likely to be true for leprosy bacilli. Good
evidence exists proving that healthy, close contacts of leprosy
patients may temporarily carry leprosy bacilli in their nasal
mucosa that can be released as potentially infective particles
[29,30].
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A disease of perturbed cellular immunity following the immu-
nopathological spectrum of the mycobacterioses (see below),
Buruli ulcer is unlike leprosy and tuberculosis. It is almost
never passed from person to person, but is rather caught from
the environment [31]. Very slow growing, even when the inoc-
ulum is taken from grossly bacilliferous lesions, it has only
very recently been cultured from the environment [32]. None-
theless, much can be learned from careful epidemiology.
Unlike leprosy and tuberculosis, where virulence and patho-
genicity are thought to be direct immuno-perturbing charac-
teristics of the bacilli, M. ulcerans causes the ulcerative and
necrotising characteristics of Buruli ulcer by its production
of a toxin [33,34]. This toxin, called ‘‘mycolactone’’ [35], is the
result of the bacilli themselves being infected with a transmis-
sible plasmid [36]. Non-toxigenic strains of M. ulcerans can
arise during prolonged artificial culture and can be recognised
by their inability to cause disease when injected experimen-
tally into mice—animals very susceptible to the toxin [37]. In
the absence of the occurrence of clinical Buruli ulcer, the envi-
ronmental distribution of non-toxigenic M. ulcerans is hard to
determine.
An assessment of the role contact with mycobacteria may
play in susceptibility to juvenile asthma was carried out in
Crete [38], an island where clinical cases of Buruli ulcer have
not been recorded. More than the expected number of chil-
dren coming from a village close to a freshwater lake re-
sponded positively to Burulin—a tuberculin made from
cultured M. ulcerans [39], indicating the probable presence of
non-toxigenic M. ulcerans in their surroundings.
Other mycobacterial diseases occurring in man
These are opportunist diseases in which the tissues of sus-
ceptible individuals are invaded from environmental sources.
They include swimming-pool granuloma caused by M. mari-
num, mycobacterial injection abscesses [40], frequently
caused by M. chelonae or M. fortuitum, and mycobacterial cervi-
cal adenitis caused by a range of slow-growing species,
including M. scrofulaceum, M. avium and M. malmoense [41].
Chronic lung disease, usually of the elderly, can be caused
by M. avium, M. intracellulare, M. kansasii and M. xenopi [42].
The Immuno-pathological spectrum of
mycobacterial infections
The concept of an immunopathological spectrum proposed
for leprosy by Ridley and Jopling [19,43] has been very influen-
tial. The spectrum embraces a series of phases related to bac-
terial growth. Prior to the spectrum, there is a latent phase
which may vary from weeks to years in length. There is then
a phase of uncontrolled bacterial growth when lesions are
bacilliferous or multi-bacillary and antibody levels are high.
As cellular immune reaction increases and antibody levels
fall, bacillary numbers are reduced and a tuberculoid state
supervenes. From the hosts viewpoint there is a stage of im-
mune suppression with rapid development of disease associ-
ated with little cellular response and a stage of slowlyprogressive or static disease as a specific cellular response
supersedes. The worst tissue destruction is usually associated
with the change from immune suppression to recognition.
Leprosy patients tend to remain either in a multi-bacillary
lepromatous state or in a paucibacillary tuberculoid state.
Those with the borderline types of disease, where most tissue
damage occurs, are associated with movement, up or down,
from suppressed to expressed cellular immune response
[43]. Tuberculosis fits less easily than does leprosy into the
spectrum, but can generally be compared with the borderline
states in leprosy according to the activity of tissue destruc-
tion. The most tuberculoid form of tuberculosis progresses
very slowly with few visible bacilli and limited tissue
destruction.
Patients developing M. ulcerans infection (Buruli ulcer) pass
through a latent phase of several weeks, into the clinical
phase when ulceration begins under the immunosuppressive
effects of mycolactone [35] and bacilli are present in millions.
For unknown reasons, perhaps owing to production of anti-
bodies that neutralise the toxin, the disease changes from
multibacillary and necrotising to paucibacillary, tuberculoid
and fibrosing [44,45] (see Fig. 2).
The Bacillus of Calmette and Guerin (BCG)
Following Jenner’s observations on vaccination, the discov-
ery and development of vaccines effective against a number
of infections took place in the second half of the 19th cen-
tury. Attempts were made in the 1870s to develop a vaccine
for tuberculosis, and Robert Koch’s work in the 1880s led to
real progress [46,47]. Calmette and Guerin developed a sus-
pension of live, attenuated bacilli isolated from a calf be-
lieved to be infected with the bovine form of tubercle
bacillus, which could protect children from active tuberculo-
sis [48]. BCG is an enhancer of cellular immunity, as were the
earlier, less well-known products. These include Spahlinger’s
vaccine produced from living, but dormant, tubercle bacilli
[49] and Friedman’s preparation of live M. chelonae [50]. BCG
gives a variable degree of protection from tuberculosis, lep-
rosy [51,52], Buruli ulcer [53], malignant melanoma [54] and
probably other cancers. We can only guess at the contribu-
tion that the widespread application of BCG vaccination
has had on the changing patterns of many other diseases.
BCG demonstrates that there is an immune response other
than that expressed in the Ridley–Jopling spectrum, and that
its efficacy is not dependent upon responses to species-spe-
cific antigens but to primitive antigens common to all bacte-
ria and to the stress proteins of animal tissues [55,56]. Once
this essential point has been grasped, progress can be made
towards the recognition and development of immuno-pro-
phylaxis and immunotherapy. BCG is the only survivor of
the early 20th century preparations of live organisms
[49,50], though Friedmann’s ‘‘Anningzochin’’ was claimed to
be effective against asthma, psoriasis and some other non-
mycobacterial diseases as well as tuberculosis. These are
claims revisited in the late 20th century and today with
the recognition of the immunomodulatory powers of M. vac-
cae, M. obuense and of selected species from other genera of
the aerobic Actinomycetales.
Fig. 2 – The immuno-pathological spectrum of the mycobacterioses. The basis of the spectrum for leprosy described by Ridley
and Jopling [19] is shown in the upper section of the figure. To the left of the clinical spectrum is the period of latent disease
and to the right of it is the period of persistent disabilities. Patients with clinical leprosy, except for those with borderline
presentations, do not shift from multibacillary, lepromatous to paucibacillary, tuberculoid forms, without the application of
immunotherapy. Untreated lepromatous disease can be life-long, whereas tuberculoid disease can be self-limiting. The
middle section shows the situation of pulmonary tuberculosis in relation to the leprosy spectrum. Active tuberculosis is more
analogous to lepromatous to borderline leprosy, and only healed cases correspond with tuberculoid leprosy. The bottom
section shows Buruli ulcer (M. ulcerans disease) in relation to the leprosy spectrum. Coming from the environment there is a
latent phase of several weeks’ duration, following which the disease passes through a multibacillary phase, analogous to
lepromatous leprosy, when rapid extension of ulceration occurs. This is followed by a very rapid reduction of bacilli with the
onset of cellular immune recognition, finishing with extensive disabilities in many cases owing to massive fibrosis.
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prophylaxis and therapy
In a search for an explanation of why BCG was so effective
against leprosy in Uganda, but had little effect in Burma,
the influence of priming by environmental species was
investigated and it was found that the fast-grower M. vaccae
enhanced protective post-BCG immune responses in Ugan-
da, and slow-growers including M. scrofulaceum blocked them
in Burma [57]. In London this could be demonstrated in lab-
oratory mice [58], and it was shown that priming with killed
M. vaccae alone also enhanced protective immune responses.
This discovery of the potential value of sensitisation to
M. vaccae came in the 1970s at the time of a great explosion
of knowledge about immunology. The old idea that protec-
tive immunity and tissue-damaging allergy were different
presentations of cellular immunity demonstrated in the
tuberculin response was proven. At first these were desig-
nated ‘‘Listeria-like’’ and ‘‘Koch-like’’ responses, respectively
[59]. These dubious terms were replaced by Th1 and Th2
as different pathways of maturation of CD4+ cells were
recognised [60].
Mycobacterium vaccae in prophylaxis
Transferred to the children of leprosy patients in Bombay [61],
Iran [62–65] and later Vietnam [66], it was shown that acombined vaccine of live BCG plus killed M. vaccae was about
50% more effective than BCG alone in the induction of corre-
lates of protective immunity, and the effect of killed M. vaccae
alone was little different from the combination. A recent
study has shown the benefits of repeated doses in preventing
tuberculosis in HIV-positive patients [67].
Mycobacterium vaccae in therapy for leprosy and tuberculosis
The potential for M. vaccae as an immuno-therapeutic for lep-
rosy was first investigated in Spain [68,69], Iran [64,70], India
[71] and Vietnam, and for tuberculosis in London [72], the
Gambia, Kuwait [73,74], Nigeria [75], Romania [76,77] and Viet-
nam [78]. Subsequent studies found a single injected dose to
be inadequate in some places, especially in HIV-infected per-
sons [79].
A series of studies of tuberculosis were carried out in
Argentina, with single injections [80], three injections [81] or
10 oral doses [82]. The principles of this type of immunother-
apy, affecting host immunity and not directly the bacilli
themselves, means that it would be equally effective against
drug-resistant bacilli, and this has proved to be the case
[73,76,83–85]. This was well demonstrated in a study at Ma-
shad in Iran. A combination of anti-bacterial chemotherapy
plus immunotherapy with M. vaccae should lead to less devel-
opment of drug resistance and to substantially shorter treat-
ment regimens.
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type 2 cytokine activity and reports of M. vaccae immuno-
therapy for pulmonary tuberculosis record a reduction in
radiological opacities and improved closure of cavities
[75,77,80].
Unexpected findings with M. vaccae
During the period of investigation of immunotherapy for
mycobacterial disease, patients and their physicians were
asked to note effects on concurrent conditions. The first to
be reported and investigated was psoriasis in a leprosy pa-
tient in South India [86], and this was confirmed in a study
from Argentina [87]. Following this observation other autoim-
mune and related conditions have been investigated. The first
of these was Raynaud’s disease and blood flow in the fingers
of leprosy patients [70], from which success with M. vaccae
led to studies of myointimal hyperplasia following balloon
damage to the carotid arteries of rats [88]. Experimental peri-
odontal disease in rats also responded to treatment with
M. vaccae [89].
There have been conflicting reports from various countries
suggesting that BCG vaccination has an effect on bronchial
asthma, but this has been difficult to confirm [38]. Studies
with M. vaccae in asthma and bronchial allergy in hay fever
showed that its use is drug sparing so far as steroids and sal-
butamol are concerned and that the effect is on the delayed
part of the immune response of airways, rather than their
immediate responses [90].
Patients treated with M. vaccae have reported a reduction
in susceptibility to the common cold and an observation
made during studies on the prevention of tuberculosis in
HIV-positive patients in Africa recorded an interesting reduc-
tion in malaria [67], which still has to be followed up. Atopic
dermatitis in children responded well to a single injected
treatment with M. vaccae, providing it was prepared in borate
buffer [91,92], though a small effect was found on chronic se-
vere dermatitis in adults, using the phosphate-buffered prep-
aration [93]. Borate buffer appears to result in a more stable
product than does the phosphate buffer, and discussions with
a glycobiologist disclosed that autoclaving in borate breaks
down proteins to short amino acid chains suitable for T cell
activation, and better preserves the bacterial sugars. A com-
parative study in Kuwait found that killing M. vaccae by auto-
claving produces a more effective product than does exposure
to Co60 [74].
Two important properties of the M. vaccae preparation are
expressed in immuno-prophylaxis and immunotherapy. The
first is the immuno-modulating adjuvant activity of the cell
wall complex down-regulating Th2 mechanisms [64]. The
other is the content of antigens cross-reactive with invading
bacteria and stressed host tissue [56], explaining the very
wide therapeutic activities of the preparation.
Mycobacteria and cancer
At one time mycobacteria were considered as possible causes
of cancer, but this has never been substantiated. However,
mycobacteria do have the capacity to prevent and treat can-
cer. During the 1970s attempts were made to use BCG vaccineas an immunotherapeutic [94]. Some benefits were claimed,
but the only successful application of BCG is by instilling it
into the bladder of patients with carcinoma in situ [95], and
currently this is the treatment of choice. The problem with
BCG is that it enhances the cellular immune response for
which the patient is already primed and does not modulate
from Th2 towards Th1 maturation of T cells, an essential
step in effective immunotherapy for cancer [96]. An exten-
sive survey has shown that past BCG vaccination reduces
susceptibility to malignant melanoma by about 50% and in-
creases the successful outcome to treatment also by 50%
[54].
With the development of M. vaccae and its use in patients
with various conditions, remarkable effects have been ob-
served in those with cancers [97–99]. Direct studies were
performed in which patients with a variety of different
malignancies received repeated intradermal injections, and
a significant improvement in quality of life [100], better toler-
ance of the side effects of chemotherapy [99] and increased
survival were achieved [98]. More recently, a combination of
injections and oral capsules containing the same dose of M.
vaccae have been used. An extensive and comprehensive list
of patients with many different kinds of cancer has been
progressing for several years and has produced some striking
results.
Another mycobacterial species, M. obuense closely related
to M. vaccae [101], was found to have similar immunothera-
peutic activity and is being developed by Immodulon Thera-
peutics Ltd. in London [102]. It is undergoing clinical trials
in malignant melanoma, carcinoma of the head of the pan-
creas and bowel cancer with liver metastases.
Immune modulation and genera related to
mycobacteria
Among the aerobic, near-mycobacterial genera, within the
Actinomycetales, are some species with adjuvant activities
and antigens very similar to those of M. vaccae, but with sub-
tle differences. Some of these species have been investigated
for therapeutic activities in human, veterinary and agricul-
tural medicine. Made in the same way as the M. vaccae prep-
aration, useful results have been obtained.
Tsukamurella inchonensis
In animal models, a preparation of this species has been par-
ticularly successful in preventing inflammation of the intima
of arteries damaged with a balloon catheter [88] and for use in
the prevention and treatment of spontaneous type 2 diabetes
mellitus. It was found that M. vaccae and T. inchonensis were
the most effective, followed by Gordonia bronchialis and with
Rhodococcus coprophilus being the least effective. Both of these
are models of important human diseases. In man, anecdotal
cases of asthma and periodontal disease treated with oral T.
inchonensis have shown benefits similar to those achieved
with M. vaccae. A marked reduction in frequency of common
colds has been observed in volunteers taking oral therapy
with T. inchonensis and patients with recurrent cold sores ow-
ing to Herpes simplex virus infection have found that the sores
are of much shorter duration, less frequent and less severe.
Currently, T. inchonensis is being investigated for potential
I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 1 ( 2 0 1 2 ) 3 –1 2 9introduction into human medicine by a new company,
Actinopharma Ltd. In veterinary medicine, T. inchonensis has
been found to be effective in the treatment of ‘‘sweet-itch’’,
a seasonal dermal allergy of horses [103], for which there is
no other effective treatment, and in ‘‘heaves’’, an allergic
respiratory airways obstructive disease of equines.
Gordonia bronchialis
Rats treated with G. bronchialis or R. coprophilus, but not with
T. inchonensis, and challenged with live Trypanosoma cruzi show
significantly reduced parasitaemias and less chronic myocar-
ditis [104]. Pregnant rats treated with G. bronchialis, but not R.
coprophilus gave birth to offspring protected from subsequent
challenge with T. cruzi [105]. Potentially, these are models of
the consequences of Chagas’ disease in man, and may have
relevance in other causes of myocardial disease. In dogs, a
preparation of G. bronchialis has been particularly effective
against allergy to flea-bites [106] and is likely to be developed
as veterinary medicine. In agricultural medicine, G. bronchialis
induces improved survival and weight gain in shrimp and
fish hatchlings and is improving growth rate and colour and
reducing skeletal abnormalities in koi carp. Treatment
with the same organism has resulted in improved growth
rates in pigs and cattle, which is now being further
investigated.
Conclusions
Among the 100 or more species of mycobacteria, M. tuberculo-
sis and M. leprae are important pathogens and amongst the
remainder are a number of species capable of becoming
opportunist pathogens, including the toxin-producing species
M. ulcerans. Within the environment, moisture, temperature,
pH, exposure to ultra-violet light and geography all have sig-
nificant influences on mycobacterial distribution. Their pres-
ence probably provides an evolutionary drive towards the
development of the immune systems of all animals.
Sensitisation of human and animal populations with locally
common species offers a method of detecting their presence
and provides a means by which susceptibility or protection
from mycobacterial and other diseases can be determined.
Killed preparations of selected mycobacteria and of species
from other genera within the order Actinomycetales are potent
immune modulators and enhancers useful in the prevention
and treatment of many diseases in which cellular immunity
plays a large part. Between them they provide products likely
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